Yuxin Mu

460 total citations
34 papers, 283 citations indexed

About

Yuxin Mu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yuxin Mu has authored 34 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Yuxin Mu's work include Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Yuxin Mu is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Yuxin Mu collaborates with scholars based in China and United States. Yuxin Mu's co-authors include Junling Li, Puyuan Xing, Xuezhi Hao, Ziyi Xu, Yan Wang, Xingsheng Hu, Li Teng, Di Ma, Jinyao Zhang and Ke Yang and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Agricultural and Food Chemistry and Chemical Engineering Journal.

In The Last Decade

Yuxin Mu

30 papers receiving 281 citations

Peers

Yuxin Mu

PRM

ONCOL

PFM

Efimia Boutsikou Greece

Stephanie P.L. Saw Singapore

Weiwei Ning China

Yasunari Kishino Japan

Giuliano Palumbo Italy

Marta Román Spain

Yan-juan Zhu China

Luigi Della Gravara Italy

Jinpo Yang China

Simona Bevilacqua Italy

Efimia Boutsikou Greece

Yuxin Mu

158 ×0.8

PRM

155 ×0.9

ONCOL

112 ×1.2

65 ×1.3

16 ×0.6

PFM

Citations per year, relative to Yuxin Mu Yuxin Mu (= 1×) peers Efimia Boutsikou

Countries citing papers authored by Yuxin Mu

Since Specialization

Citations

This map shows the geographic impact of Yuxin Mu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuxin Mu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuxin Mu more than expected).

Fields of papers citing papers by Yuxin Mu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuxin Mu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuxin Mu. The network helps show where Yuxin Mu may publish in the future.

Co-authorship network of co-authors of Yuxin Mu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuxin Mu. A scholar is included among the top collaborators of Yuxin Mu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuxin Mu. Yuxin Mu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhong, Kejun, Jie Xiang, Yu Liu, et al.. (2025). Fabrication of a high strength, swelling resistance, and conductive hydrogel for flexible underwater sensor via ketalization. Chemical Engineering Journal. 511. 161885–161885. 8 indexed citations

Yao, Ting, et al.. (2025). Self-healing and recyclable thermosetting polyurethanes based on dynamic imine and phenol-carbamate bonds. Polymer. 344. 129528–129528.

Zhang, Jianguo, Yuxin Mu, Hui Zhang, et al.. (2025). Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting. Frontiers in Oncology. 15. 1564888–1564888.

Wang, Yating, Kejun Zhong, Yuxin Mu, et al.. (2025). A janus hydrogel with high strength, adhesive and conductive for wearable strain sensor. Polymer. 323. 128210–128210. 7 indexed citations

Meng, Yanchun, Xiaojun Liu, Yuxin Mu, et al.. (2024). Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.. Journal of Clinical Oncology. 42(16_suppl). e14600–e14600. 1 indexed citations

Zhang, Jian, Yiqun Du, Yanchun Meng, et al.. (2024). First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. npj Precision Oncology. 8(1). 200–200. 2 indexed citations

Huan, Jinliang, Xiaojun Liu, Na Wang, et al.. (2024). The RRP9-JUN axis promotes breast cancer progression via the AKT signalling pathway. Biology Direct. 19(1). 131–131. 1 indexed citations

Liu, Yu, Huawei Liu, Xinyu Tian, et al.. (2023). Effects of Lactiplantibacillus plantarum on oxidative stress, mitophagy, and NLRP3 inflammasome activation in broiler breast meat. Poultry Science. 102(12). 103128–103128. 11 indexed citations

Mu, Yuxin, Xinyu Tian, Huawei Liu, et al.. (2023). Hepatic Proteomics Analysis Reveals Attenuated Endoplasmic Reticulum Stress in Lactiplantibacillus plantarum-Treated Oxidatively Stressed Broilers. Journal of Agricultural and Food Chemistry. 71(30). 11726–11739. 2 indexed citations

10.

Wang, Jiani, Lin Gui, Yuxin Mu, et al.. (2023). Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors. BMC Cancer. 23(1). 1200–1200.

11.

Li, Yan, Ziyi Xu, Yixiang Zhu, et al.. (2022). Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic Cancer. 13(15). 2201–2209. 10 indexed citations

12.

Mu, Yuxin, Xuezhi Hao, Puyuan Xing, et al.. (2020). Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology. 146(9). 2427–2433. 53 indexed citations

13.

Mu, Yuxin, Ke Yang, Xuezhi Hao, et al.. (2020). Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. Frontiers in Oncology. 10. 603–603. 21 indexed citations

14.

Xing, Puyuan, Nong Yang, Yuxin Mu, et al.. (2020). The clinical significance of RET gene fusion among Chinese patients with lung cancer. Translational Cancer Research. 9(10). 6455–6463. 4 indexed citations

15.

Li, Qing, Jiani Wang, Yuxin Mu, et al.. (2020). Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chinese Journal of Cancer Research. 32(4). 485–496. 10 indexed citations

16.

Hao, Xuezhi, Yixiang Zhu, Yuxin Mu, et al.. (2020). Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen. Journal of Cancer. 11(21). 6421–6428. 1 indexed citations

17.

Xing, Puyuan, Yuxin Mu, Xuezhi Hao, Y. Wang, & Junling Li. (2019). Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clinical & Translational Oncology. 21(10). 1424–1431. 20 indexed citations

18.

Wang, Shouzheng, Puyuan Xing, Ke Yang, et al.. (2019). Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic Cancer. 10(6). 1461–1468. 8 indexed citations

19.

Mu, Yuxin, Puyuan Xing, Xuezhi Hao, Y. Wang, & Junling Li. (2018). P3.13-17 A Retrospective Study: Central Nervous System Response to Osimertinib in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S982–S983. 1 indexed citations

20.

Mu, Yuxin, Pin Zhang, Fei Ma, et al.. (2018). [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].. PubMed. 40(7). 506–511. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact